Amgen's office in Austria: Franz Josefs Kai Vienna
Business Address: Franz Josefs Kai 47 1010 Vienna
Phone: +61150217
Fax: 43 (0)1 253 672 272 37
E-mail: eu-at-complaint@amgen.com
Web: https://www.amgen.at
| Formerly | Applied Molecular Genetics (1980–1983) |
|---|---|
| Type | Public |
| Traded as |
|
| ISIN | |
| Industry | Biotechnology |
| Founded | April 8, 1980 (1980-04-08) |
| Headquarters | Thousand Oaks, California, U.S. |
| Key people | Robert A. Bradway (Chairman, President, & CEO) |
| Products | Aimovig, Aranesp, Blincyto, Epogen, Kineret, Enbrel, Kyprolis, Neulasta, Neupogen, Nplate, Parsabiv, Prolia, Repatha, Sensipar/Mimpara, Vectibix, Xgeva |
| Revenue |  US$25.424 billion (2020) |
| Operating income |  US$9.672 billion (2019) |
| Net income | US$7.842 billion (2019) |
| Total assets | US$59.707 billion (2019) |
| Total equity | US$9.675 billion (2019) |
| Number of employees | 22,000 (February 2020) |
| Website | amgen.com |
Amgen is one of the world’s leading biotechnology companies. Amgen is a values-based company, deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious illnesses. At Amgen, we believe in a “biology first” approach. We use cutting-edge science and technology to study the subtlest biological mechanisms in search of therapies that will improve the lives of those who suffer from serious diseases. Amgen believes the cure for disease can be found inside each and every one of us.